Join our daily newsletter At The Bell to receive exclusive market insights
- Telix Pharmaceuticals (TLX) recruits more than 50 per cent of patients required for its ZIRCON phase three study for imaging renal cancer
- The trial will treat around 250 renal cancer patients undergoing kidney surgery to determine the sensitivity and specificity of its drug, TLX250-CDx
- The study has exceeded enrolment expectations despite reduced numbers over the last twelve months due to COVID-19, with between five and ten patients enlisted per week
- Telix says it expects the trial to complete recruitment over the next four to five months, subject to ongoing pandemic conditions
- Telix Pharmaceuticals was up 4.34 per cent, trading at $5.29 at 12:50 pm AEST
Telix Pharmaceuticals (TLX) has exceeded 50 per cent recruitment for its ZIRCON phase three study for imaging renal cancer.
The trial investigates the drug TLX250-CDx provided from Telix’s manufacturing and dispensing sites in Canada, Turkey, the US and the Netherlands. The study looks to determine whether renal masses in patients are either clear cell renal cell cancer (ccRCC) or non-ccRCC by using Positron Emission Tomography imaging.
The company says having an imaging agent that will predict clear cell kidney cancer prior to treatment will spare patients having to undergo unnecessary biopsies and limit unnecessary surgeries.
The trial will treat around 250 renal cancer patients undergoing kidney surgery to determine the sensitivity and specificity of TLX250-CDx.
The study has exceeded enrolment expectations, despite reduced numbers over the last twelve months due to COVID-19. Around 80 per cent of sites in the study have returned to recruiting for clinical trials, seeing between five and ten patients enlisted per week.
Telix expects to complete recruitment over the next four to five months, subject to ongoing pandemic conditions.
Telix Chief Medical Officer Dr Colin Hayward says it’s pleasing to see the trial accelerating and a resumption to normal clinical operating conditions.
“The feedback we are receiving from investigators is very positive and the company remains on track to achieve its stated objective of completing the trial this year, thus progressing a second FDA marketing authorisation submission after the Illuccix prostate cancer imaging program,” said Dr Colin Hayward.
Additionally, Telix expects to commence the FDA Biologics License Application (BLA) consultation process before end-calendar year, which is on schedule.
Telix Pharmaceuticals was up 4.34 per cent, trading at $5.29 at 12:50 pm AEST.
